The drugstore lobby's attempts to force pharmacy benefit managers to disclose confidential business information will only raise costs for consumers and governments, according to a study published in the Cornell Law Review Online. These proposed state laws "foster tacit collusion and reduce PBMs' ability to negotiate discounts with pharmacies and rebates with drug manufacturers," author Joanna Shepherd writes. "By disrupting competition in the prescription drug market, mandatory disclosure regulations will ultimately increase the prices that consumers pay for prescription drugs."

Full Story:
RxObserver blog

Related Summaries